Navigation Links
Quincy Bioscience Announces Encouraging Preliminary Results of Randomized, Double-Blind, Placebo-Controlled Memory Study
Date:6/24/2010

Quincy Bioscience, a research-based biotechnology company, announced interim results from the Prevagen Memory Study. The Prevagen Memory Study is a three-month long, randomized, double-blind, placebo controlled study using both qualitative Quality of Life surveys and a quantitative, computer-based set of cognitive tests developed by Cogstate Ltd.

Madison, WI (Vocus) June 24, 2010 -- Quincy Bioscience, a research-based biotechnology company, announced interim results from the Prevagen Memory Study. The Prevagen Memory Study is a three-month long, randomized, double-blind, placebo controlled study using both qualitative Quality of Life surveys and a quantitative, computer-based set of cognitive tests developed by Cogstate Ltd.

Prevagen showed statistically significant improvement over placebo at Day 60 in measures of spatial working memory and executive function in thirty five generally healthy adults reporting memory concerns prior to the start of the trial. The Prevagen arm showed a 14% reduction in the number of total errors compared to Day 0. The average age of this initial cohort was 61 years old and sixty eight percent of the participants were female. A statistically significant improvement was also seen in the change from baseline (Day 0) measurements. “We are encouraged by what this preliminary look at the data from this study has shown us,” said KC Lerner, Manager of Business Development.

Prevagen contains the calcium-binding protein apoaequorin. Apoaequorin has demonstrated neuroprotection in pre-clinical studies performed at the University of Wisconsin-Milwaukee. Apoaequorin was originally isolated from Aequorea victoria, a species of jellyfish found in the Puget Sound.

“The relationship between intracellular calcium imbalance and age-related cognitive decline is well-established. The data shows that Prevagen is a new tool for staying cognitively fit as we age. With 78 million baby boomers getting older every day, helping people with memory concerns is our first priority,” said Quincy Bioscience President Mark Underwood. Quincy Bioscience is also looking at several health conditions that are believed to be the result of disruptions in calcium homeostasis and intends to study the effect of Prevagen in these conditions.

About Quincy Bioscience
Quincy Bioscience is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company's products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms.

###

Read the full story at http://www.prweb.com/releases/quincybioscience/memorydata/prweb4188374.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Quincy Bioscience Launches HOPETrials.com; Research Studies More Accessible For Participants
2. Quincy Bioscience Sponsors Multiple Sclerosis (MS) Scholarship Program
3. Euthymics Bioscience Collaborates with GlobalSign and SafeNet to Provide an FDA Approved Electronic Signature Solution
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2009 Financial Results
5. Thriving Bioscience Region Leaves Its Mark
6. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
7. Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services
8. Southridge LLC Provides Equity Capital Through Private Agreement with PuraMed Bioscience
9. Digital Pathology Services Firm Flagship Biosciences Appoints New CEO
10. Exalenz Bioscience Expands Market Coverage for the BreathID Breath Test System
11. Martek Biosciences and the National Center for Creative Aging Introduce New Brain Health Awareness Campaign, "Beautiful Minds: Finding Your Lifelong Potential"
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Quincy Bioscience Announces Encouraging Preliminary Results of Randomized, Double-Blind, Placebo-Controlled Memory Study
(Date:6/27/2016)... , ... June 27, 2016 , ... ... , the only authorized OSHA Training Institute Education Center headquartered in Northern California, ... their workers from extreme heat at their worksites. Employers with workers exposed ...
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Cut Pro X users can now reveal the media of their split screens ...
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... California (PRWEB) , ... June ... ... pioneer in the patient payment industry today announced its strategic partnership with ... health system workflows. , The two companies’ proven, proprietary technology combine to ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... technology to revolutionize the emergency ambulance transport experience for the millions of people ... how Uber has disrupted the taxi industry through the use of technology. Now, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Australia,s successful biotechnology scientists, Dr Graham ... Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is seeking ... ASX. Noxopharm is a clinic-ready company with its first ... study later this year. NOX66 ... cancer patients - the ability of cancers to become resistant to ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology: